https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32668 Wed 19 Jan 2022 15:16:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36948 Wed 19 Jan 2022 15:16:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18377 Wed 11 Apr 2018 15:30:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26012 Wed 11 Apr 2018 14:44:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24771 Staphylococcus aureus (MRSA) bacteraemia is a serious infection resulting in 20–50 % 90-day mortality. The limitations of vancomycin, the current standard therapy for MRSA, make treatment difficult. The only other approved drug for treatment of MRSA bacteraemia, daptomycin, has not been shown to be superior to vancomycin. Surprisingly, there has been consistent in-vitro and in-vivo laboratory data demonstrating synergy between vancomycin or daptomycin and an anti-staphylococcal β-lactam antibiotic. There is also growing clinical data to support such combinations, including a recent pilot randomised controlled trial (RCT) that demonstrated a trend towards a reduction in the duration of bacteraemia in patients treated with vancomycin plus flucloxacillin compared to vancomycin alone. Our aim is to determine whether the addition of an anti-staphylococcal penicillin to standard therapy results in improved clinical outcomes in MRSA bacteraemia. Methods/Design: We will perform an open-label, parallel-group, randomised (1:1) controlled trial at 29 sites in Australia, New Zealand, Singapore, and Israel. Adults (aged 18 years or older) with MRSA grown from at least one blood culture and able to be randomised within 72 hours of the index blood culture collection will be eligible for inclusion. Participants will be randomised to vancomycin or daptomycin (standard therapy) given intravenously or to standard therapy plus 7 days of an anti-staphylococcal β-lactam (flucloxacillin, cloxacillin, or cefazolin). The primary endpoint will be a composite outcome at 90 days of (1) all-cause mortality, (2) persistent bacteraemia at day 5 or beyond, (3) microbiological relapse, or (4) microbiological treatment failure. The recruitment target of 440 patients is based on an expected failure rate for the primary outcome of 30 % in the control arm and the ability to detect a clinically meaningful absolute decrease of 12.5 %, with a two-sided alpha of 0.05, a power of 80 %, and assuming 10 % of patients will not be evaluable for the primary endpoint. Discussion: Key potential advantages of adding anti-staphylococcal β-lactams to standard therapy for MRSA bacteraemia include their safety profile, low cost, and wide availability. Trial registration: ClinicalTrials.gov Identifier: NCT02365493. Registered 24 February 2015.]]> Wed 11 Apr 2018 11:47:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22606 16 years) were admitted with confirmed influenza to one of 15 of 17 FluCAN sentinel hospitals (excluding 2 paediatric hospitals). Of these, 47% were over 65 years of age, 10% were Indigenous Australians, 3.3% were pregnant and 85% had chronic co-morbidities. The majority of cases were due to influenza A. Influenza B was detected in 7% of patients. There were a large number of hospital admissions detected with confirmed influenza in this national observational surveillance system in 2014. These are estimated to represent a national annual burden of around 15,000 admissions and almost 100,000 bed-days nationally.]]> Wed 11 Apr 2018 10:29:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41418 Wed 03 Aug 2022 11:59:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41960 Tue 30 Apr 2024 08:49:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30212 Tue 28 Jan 2020 14:54:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50428 Tue 25 Jul 2023 18:54:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48576 Tue 21 Mar 2023 17:22:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44236 Tue 11 Oct 2022 11:46:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35825 Tue 10 Dec 2019 11:47:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45042 Thu 27 Oct 2022 13:54:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54275 Thu 15 Feb 2024 14:39:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52205 Thu 05 Oct 2023 10:15:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42697 Thu 01 Sep 2022 09:44:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7639 Sat 24 Mar 2018 08:36:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13301 Sat 24 Mar 2018 08:18:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12440 Sat 24 Mar 2018 08:15:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17178 Sat 24 Mar 2018 08:06:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28621 Sat 24 Mar 2018 07:38:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27042 Sat 24 Mar 2018 07:25:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24751 Clostridium difficile rose in prominence in the early 2000s with large-scale outbreaks of a particular binary toxin-positive strain, ribotype 027, in North America and Europe. In Australia outbreaks of the same scale had not and have not been seen. A survey of C. difficile across Australia was performed for 1 month in 2010. A collection of 330 C. difficile isolates from all States and Territories except Victoria and the Northern Territory was amassed. PCR ribotyping revealed a diverse array of strains. Ribotypes 014/020 (30.0%) and 002 (11.8%) were most common, followed by 054 (4.2%), 056 (3.9%), 070 (3.6%) and 005 (3.3%). The collection also contained few binary toxin positive strains, namely 027 (0.9%), 078 (0.3%), 244 (0.3%), 251 (0.3%) and 127 (0.3%). The survey highlights the need for vigilance for emerging strains in Australia, and gives an overview of the molecular epidemiology of C. difficile in Australia prior to an increase in incidence noted from mid-2011.]]> Sat 24 Mar 2018 07:14:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23340 Sat 24 Mar 2018 07:13:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36574 Mon 24 Jul 2023 18:02:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38446 Mon 09 May 2022 16:20:08 AEST ]]>